Bristol-Myers Squibb

October 17, 2017October 17, 2017

Opdivo, Alone or Combined with Yervoy, Extends Lung Cancer Patients’ Survival, Phase 1/2 Trial Shows

Lung Cancer, News

Opdivo (nivolumab) has shown promise as a treatment for recurring small lung cancer patients who have a lot of genetic errors in their tumors, according to a Phase 1/2 clinical trial. ... Read more

April 18, 2017April 19, 2017

Bristol-Myers, Nordic Partnering on Development of Biomarkers for Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Bristol-Myers Squibb and Nordic Bioscience have agreed to work together to develop biomarkers for diagnosing and monitoring patients with fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). IPF is a fatal, rare lung ... Read more

September 7, 2015September 7, 2015

US FDA Accepts Bristol-Myers Squibb’s sBLA for Opdivo (nivolumab) to Include Previously Treated Squamous NSCLC

Lung Cancer, News

The US Food and Drug Administration recently accepted Bristol-Myers Squibb Company’s supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for review as a treatment for previously treated patients with non-squamous (NSQ) non-small cell ... Read more

July 21, 2015July 21, 2015

European Commission Approves Nivolumab BMS by Bristol-Myers Squibb for NSCLC

Lung Cancer, News

Bristol-Myers Squibb Company recently announced the European Commission has granted approval of Nivolumab BMS as an effective post-chemotherapy treatment for locally advanced or metastatic squamous (SQ) non-small cell lung cancer ... Read more

July 17, 2015July 17, 2015

Bristol-Myers and MUSC Collaborate to Study IPF, Scleroderma

News

Bristol-Myers Squibb Company and the Medical University of South Carolina (MUSC) have recently announced the signing of an agreement to study fibrotic diseases. The translational research collaboration is focused on diseases such as ... Read more

March 9, 2015March 9, 2015

FDA Approves Nivolumab for the Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration recently approved the medication nivolumab (Opdivo; Bristol-Myers Squibb Company) as a therapy for patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on ... Read more

November 14, 2014November 14, 2014

$7 Million Grant Seeks To Reduce Burden Of Lung Cancer In Kentucky

Lung Cancer, News

The University of Kentucky, the University of Louisville and the Lung Cancer Alliance recently renounced the launch of the Kentucky LEADS project (Lung Cancer. Education. Awareness. Detection. Survivorship) which aims to reduce ... Read more

June 12, 2014June 13, 2014

Cancer Center In New Jersey To Launch Lung Cancer Study For Nivolumab

Lung Cancer

A new experimental drug targeting lung cancer is currently being studied in an ongoing clinical trial at the Hunterdon Regional Cancer Center in New Jersey. Nivolumab is a human monoclonal antibody ... Read more